FI4051688T3 - Cd73:n estäjiä - Google Patents
Cd73:n estäjiä Download PDFInfo
- Publication number
- FI4051688T3 FI4051688T3 FIEP20883288.1T FI20883288T FI4051688T3 FI 4051688 T3 FI4051688 T3 FI 4051688T3 FI 20883288 T FI20883288 T FI 20883288T FI 4051688 T3 FI4051688 T3 FI 4051688T3
- Authority
- FI
- Finland
- Prior art keywords
- compound
- pharmaceutically acceptable
- cancer
- acceptable salt
- salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962928138P | 2019-10-30 | 2019-10-30 | |
| US202062987806P | 2020-03-10 | 2020-03-10 | |
| US202063088646P | 2020-10-07 | 2020-10-07 | |
| PCT/US2020/057996 WO2021087136A1 (en) | 2019-10-30 | 2020-10-29 | Cd73 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4051688T3 true FI4051688T3 (fi) | 2025-06-27 |
Family
ID=75686256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20883288.1T FI4051688T3 (fi) | 2019-10-30 | 2020-10-29 | Cd73:n estäjiä |
Country Status (19)
| Country | Link |
|---|---|
| US (7) | US11530236B2 (https=) |
| EP (2) | EP4051688B1 (https=) |
| JP (2) | JP7544815B2 (https=) |
| KR (2) | KR102653726B1 (https=) |
| CN (2) | CN116854758A (https=) |
| AU (1) | AU2020375914B2 (https=) |
| CA (1) | CA3159248C (https=) |
| DK (1) | DK4051688T3 (https=) |
| ES (1) | ES3034168T3 (https=) |
| FI (1) | FI4051688T3 (https=) |
| HU (1) | HUE072504T2 (https=) |
| IL (2) | IL308293B2 (https=) |
| MX (1) | MX2022005256A (https=) |
| PL (1) | PL4051688T3 (https=) |
| PT (1) | PT4051688T (https=) |
| SI (1) | SI4051688T1 (https=) |
| TW (1) | TWI830962B (https=) |
| WO (1) | WO2021087136A1 (https=) |
| ZA (1) | ZA202204941B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018208980A1 (en) | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| US11377469B2 (en) | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| CN112423764A (zh) | 2018-04-30 | 2021-02-26 | 欧瑞克制药公司 | Cd73抑制剂 |
| US12544391B2 (en) | 2019-07-16 | 2026-02-10 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| HUE072504T2 (hu) | 2019-10-30 | 2025-11-28 | Oric Pharmaceuticals Inc | CD73-inhibitorok |
| CN119173276A (zh) | 2022-04-13 | 2024-12-20 | 吉利德科学公司 | 用于治疗表达Trop-2的癌症的组合疗法 |
| WO2024059609A1 (en) * | 2022-09-14 | 2024-03-21 | Oric Pharmaceuticals, Inc. | Pharmaceutical forms of a cd73 inhibitor |
| US20240140979A1 (en) * | 2022-10-03 | 2024-05-02 | Teon Therapeutics, Inc. | Heterocyclic inhibitors of cd73 for treatment of disease |
| WO2024076873A1 (en) * | 2022-10-03 | 2024-04-11 | Teon Therapeutics, Inc. | Heterocyclic inhibitors of cd73 for treatment of disease |
| WO2025111247A1 (en) * | 2023-11-20 | 2025-05-30 | Oric Pharmaceuticals, Inc. | Treatment of refractory multiple myeloma |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025233264A1 (en) | 2024-05-07 | 2025-11-13 | Innate Pharma | Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1023991A (en) | 1911-07-29 | 1912-04-23 | Firm B Byers | Anti-rail-creeper and splice-bar. |
| EP0477454A1 (en) | 1990-09-28 | 1992-04-01 | Merrell Dow Pharmaceuticals Inc. | Novel phosphonate derivatives of certain nucleosides |
| WO2002048165A2 (en) | 2000-12-15 | 2002-06-20 | Pharmasset Ltd. | Antiviral agents for treatment of flaviviridae infections |
| US20040229839A1 (en) | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| WO2005020885A2 (en) | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| WO2007139946A2 (en) | 2006-05-25 | 2007-12-06 | University Of Tennessee Research Foundation | Gpcr ligands identified by computational modeling |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
| US20090274686A1 (en) | 2008-05-02 | 2009-11-05 | Yat Sun Or | Nucleoside phosphonate derivatives |
| WO2015164573A1 (en) | 2014-04-25 | 2015-10-29 | Vitae Pharmaceuticals, Inc. | Purine derivatives as cd73 inhibitors for the treatment of cancer |
| CN104530166B (zh) | 2014-12-04 | 2016-08-24 | 陕西汉江药业集团股份有限公司 | 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法 |
| EA036379B1 (ru) * | 2014-12-12 | 2020-11-02 | Блубёрд Био, Инк. | Химерные антигенные рецепторы к bcma |
| WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| HUE063388T2 (hu) * | 2016-01-08 | 2024-01-28 | Arcus Biosciences Inc | Ekto-5'-nukleotidáz modulátorok és ezek alkalmazása |
| TWI767937B (zh) | 2016-09-09 | 2022-06-21 | 美商卡利泰拉生物科技公司 | 外核苷酸酶抑制劑及其使用方法 |
| CN110049767B (zh) * | 2016-10-03 | 2023-04-04 | 艾库斯生物科学有限公司 | 腺苷5′-核苷酸酶的抑制剂 |
| EP3541396A4 (en) | 2016-11-18 | 2020-07-22 | Arcus Biosciences, Inc. | CD73-MEDIATED IMMUNOSUPPRESSION INHIBITORS |
| JP7138351B2 (ja) | 2016-12-22 | 2022-09-16 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | エクトヌクレオチダーゼ阻害剤およびその使用方法 |
| US20200115404A1 (en) * | 2017-03-31 | 2020-04-16 | Peloton Therapeutics, Inc. | Cd73 inhibitors and uses thereof |
| WO2018208727A1 (en) * | 2017-05-08 | 2018-11-15 | Eternity Bioscience Inc. | Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof |
| WO2018208980A1 (en) | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| US11377469B2 (en) | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| WO2019129059A1 (zh) | 2017-12-29 | 2019-07-04 | 上海和誉生物医药科技有限公司 | 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用 |
| CN112423764A (zh) | 2018-04-30 | 2021-02-26 | 欧瑞克制药公司 | Cd73抑制剂 |
| EP3810109B1 (en) | 2018-05-31 | 2024-08-07 | Peloton Therapeutics, Inc. | Compounds and compositions for inhibiting cd73 |
| AU2019288495B2 (en) | 2018-06-21 | 2024-02-08 | Antengene Therapeutics Limited | Ectonucleotidase inhibitors and methods of use thereof |
| EP3843714B1 (en) | 2018-08-27 | 2025-11-12 | Arcus Biosciences, Inc. | Cd73 inhibitors |
| KR20220024629A (ko) | 2019-06-20 | 2022-03-03 | 칼리테라 바이오사이언시즈, 인코포레이티드 | 엑토뉴클레오티다제 억제제 및 이의 사용 방법 |
| US12544391B2 (en) | 2019-07-16 | 2026-02-10 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| HUE072504T2 (hu) | 2019-10-30 | 2025-11-28 | Oric Pharmaceuticals Inc | CD73-inhibitorok |
-
2020
- 2020-10-29 HU HUE20883288A patent/HUE072504T2/hu unknown
- 2020-10-29 EP EP20883288.1A patent/EP4051688B1/en active Active
- 2020-10-29 US US17/083,871 patent/US11530236B2/en active Active
- 2020-10-29 IL IL308293A patent/IL308293B2/en unknown
- 2020-10-29 TW TW109137697A patent/TWI830962B/zh active
- 2020-10-29 MX MX2022005256A patent/MX2022005256A/es unknown
- 2020-10-29 PT PT208832881T patent/PT4051688T/pt unknown
- 2020-10-29 ES ES20883288T patent/ES3034168T3/es active Active
- 2020-10-29 EP EP25170469.8A patent/EP4596048A3/en active Pending
- 2020-10-29 KR KR1020227018155A patent/KR102653726B1/ko active Active
- 2020-10-29 US US17/771,711 patent/US12577272B2/en active Active
- 2020-10-29 AU AU2020375914A patent/AU2020375914B2/en active Active
- 2020-10-29 KR KR1020247010203A patent/KR102727229B1/ko active Active
- 2020-10-29 PL PL20883288.1T patent/PL4051688T3/pl unknown
- 2020-10-29 DK DK20883288.1T patent/DK4051688T3/da active
- 2020-10-29 WO PCT/US2020/057996 patent/WO2021087136A1/en not_active Ceased
- 2020-10-29 CN CN202310805820.7A patent/CN116854758A/zh active Pending
- 2020-10-29 SI SI202030633T patent/SI4051688T1/sl unknown
- 2020-10-29 IL IL292570A patent/IL292570B2/en unknown
- 2020-10-29 FI FIEP20883288.1T patent/FI4051688T3/fi active
- 2020-10-29 JP JP2022525101A patent/JP7544815B2/ja active Active
- 2020-10-29 CN CN202080091505.7A patent/CN114929721B/zh active Active
- 2020-10-29 CA CA3159248A patent/CA3159248C/en active Active
- 2020-12-08 US US17/114,993 patent/US11028120B2/en active Active
-
2021
- 2021-03-17 US US17/204,272 patent/US11130778B2/en active Active
-
2022
- 2022-05-05 ZA ZA2022/04941A patent/ZA202204941B/en unknown
- 2022-10-31 US US18/051,125 patent/US12018043B2/en active Active
-
2024
- 2024-05-10 US US18/660,815 patent/US12454544B2/en active Active
- 2024-08-15 JP JP2024135814A patent/JP7688769B2/ja active Active
-
2025
- 2025-10-22 US US19/365,693 patent/US20260042794A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4051688T3 (fi) | Cd73:n estäjiä | |
| PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| IL295569A (en) | Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha | |
| FI3727461T3 (fi) | EPHA2:lle spesifisiä bisyklisiä peptidiligandeja | |
| JP2019535720A5 (https=) | ||
| FI4249456T3 (fi) | Psma:ta sitova kaksoismuotoinen radioaktiivinen merkkiaine ja terapeuttinen aine | |
| PH12022551574A1 (en) | Egfr inhibitors | |
| ZA202102202B (en) | Androgen receptor modulators and methods for their use | |
| SG11201907038WA (en) | Quinazoline compound | |
| AU2016256469A8 (en) | Methods for treating cancer | |
| JP2019529500A5 (https=) | ||
| MX2021012501A (es) | Inhibidores de complejo represivo polycomb 2 (prc2). | |
| FI3660004T3 (fi) | Yhdisteitä ja menetelmiä androgeenireseptorin kohdennettuun hajotukseen | |
| GEAP202415883A (en) | Macrocyclic compounds as sting agonists and methods and uses thereof | |
| MX2021005075A (es) | Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion. | |
| FI4010329T3 (fi) | Deuteroituja yhdisteitä käytettäviksi syövän hoidossa | |
| EP4446301A3 (en) | Heterocyclic compounds for cancer imaging and treatment and methods for their use | |
| PH12021550443A1 (en) | Pyridazinones and methods of use thereof | |
| CR20240312A (es) | Macrociclos de imidazol para el tratamiento de enfermedades autoinmunitarias | |
| AR108265A1 (es) | Derivados de feniltriazol sustituidos con amida y usos de estos | |
| RU2017138468A (ru) | Антитела против человеческого her3, имеющие низкое содержание фукозы, и области их применения | |
| MX2021010870A (es) | Bloqueadores de canales ionicos cargados y metodos de uso. | |
| MX2021000941A (es) | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar canceres que incluyen los mismos. | |
| MX2017009624A (es) | Macrociclos de piridazinona como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos. | |
| MX2024002229A (es) | Formas solidas de inhibidores de apolipoproteina l1 (apol1) espirotriciclicos y metodos de uso de las mismas. |